INTRODUCTION AND OBJECTIVES: Treatment planning for adrenal tumors depends on a variety of qualitative and quantitative data, including tumor nature and anatomy, as well as the experience of the operating surgeon. Here, we have developed and propose a scoring system for adrenal masses designated as the A.D.R.E.N.A.L Score, to quantify the nature and anatomical characteristics of adrenal masses based on endocrinological assessment, computerized tomography and patient habitus.
METHODS: The A.D.R.E.N.A.L score consists of 7 components including (A)ldosterone/cortisol/catecholamine secretion or suspicion of malignancy based on endocrinological and radiological study, (D)imension (tumor size as the maximal diameter), (R)elationship to adjacent organs, (E)nhancement on computerized tomography, (N)earness of the tumor to major vessels, (A)dipose (patient habitus as body mass index), and a combination of two CONCLUSIONS: Standardized evaluation of an adrenal tumor is essential for individualized patient preparation, surgical planning and postoperative care which translate to patient safety and cost-effectiveness. The A.D.R.E.N.A.L score is a reproducible classification system based on endocrinological, oncological and anatomical characteristics of adrenal masses. This novel scoring system of adrenal masses may provide a common reference for the decision making of both endocrinologist and urologist, assessment of the surgical risks, patient safetyguided designing of adrenalectomy training programs, and stratified analysis and comparisons of adrenal surgeries within a single or among multiple institutions. INTRODUCTION AND OBJECTIVES: Partial Adrenalectomy (PA) has dramatically changed the treatment of patients affected by pathologies that affect both adrenal glands. Currently, evidences regarding the use of PA to treat primary macronodular adrenal hyperplasia(PMAH) are limited, including a small number of cases described as part of cohorts related to a variety of adrenal gland tumors. To date, the outcomes of this surgical treatment on hypercortisolism control is not known. In order to overcome the hormonal replacement caveats while minimizing the risks of hypercortisolism relapse, we performed a series of simultaneous total adrenalectomy of largest adrenal gland and contra-lateral partial adrenalectomy(adrenal sparing surgery) in patients with PMAH.
METHODS: Ten patients diagnosed with PMAH were treated surgically with adrenal sparing surgery. Primary endpoint was hypercortisolism remission, considered when patients had physiologic cortisol levels (5-25 mg/L) without hormonal reposition. Adrenal insufficiency and latent adrenal insufficiency were defined when oral hydrocortisone reposition was needed, with the dose of > 0,2 mg/kg/day and ¼ 0,2 mg/kg/day, respectively.Secondary endpoints were clinical and metabolic parameters improvement. Body mass index (BMI), blood pressure, cholesterol, lipid and glucose levels, were measured before and 12 months after the procedure. Medications to control comorbidities were also assessed and compared.
RESULTS: There were no intra-operative complications and average operation time was 189 AE 34 minutes. Median hospitalization period was 7,5 days and one patient needed surgical hematoma drainage. With a median follow-up of 24 months (range: 13 to 63 months), 40% of the cohort had complete hypercortisolism remission, 20% persisted with latent adrenal insufficiency and 40% with adrenal insufficiency. Hypercortisolism recurrence was not observed. Median systolic/diastolic blood pressures were 155/95 before and 123/80 after the procedure (p < 0,001). Median number of medications to control blood hypertension diminished from 3 to 1(p < 0,001). There was no significant change in cholesterol, lipid and glucose blood levels as well as the number of diabetes and lipid lowering medications. Median BMI decreased from 31,7 AE 7,8 to 28,4 AE 4,7(p ¼ 0.05).
CONCLUSIONS: An early assessment revealed that adrenal sparing surgery is a feasible procedure to treat patients affected by Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e477
